Chester County News and Community Website
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) recently announced 28-day data from the second dose cohort, at the 100 million cell dose level, in the DesCAARTes™ Phase 1 clinical …
Read More
WASHINGTON, D.C. — The Department of Veterans Affairs’ Office of Research and Development transitioned all its research sites nationwide and its Central Institutional Review Board, June 30, to the IRBNet …
Read More
HORSHAM, PA — Clinical Ink, a global clinical trial technology company, recently announced that CBO Jonathan Andrus has been selected to co-lead the Decentralized Trials & Research Alliance’s (DTRA) Initiative …
Read More
WASHINGTON, D.C. — The following quote is attributed to Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in …
Read More
RADNOR, PA — NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage pharmaceutical company, announced positive data from its ZYESAMI™ (Aviptadil) Expanded Access Protocol (EAP). Overall, patients receiving at least one dose of …
Read More
MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, recently announced presentation of data from …
Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, this week announced positive topline results from its Phase …
Read More
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced the release of the abstract containing interim data from the first 19 patients in its pilot Phase 1/2 clinical trial designed …
Read MoreThe U.S. Food and Drug Administration recently announced that it has awarded six new clinical trial research grants to principal investigators from academia and industry totaling over $16 million over …
Read More
BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced dosing of the first …
Read More